New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
08:07 EDTGALTGalectin Therapeutics secures GR-MD-02 U.S. patent
Galectin Therapeutics announced that the U.S. Patent and Trademark Office issued patent number 8,658,787 to the company for its application titled "Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease." The patent covers the company's carbohydrate-based galectin inhibitor compound GR-MD-02 for use in patients with fatty liver disease with or without fibrosis or cirrhosis, providing patent protection through 2031. Galectin Therapeutics is currently conducting a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 over four weekly doses of GR-MD-02 treatment in patients with fatty liver disease with advanced fibrosis. Last month, the company announced that patient enrollment in the first cohort of the Phase 1 trial was complete and results are expected to be announced around the end of 1Q14.
News For GALT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for GALT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use